Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD Antimuscarinic
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 30
Healthy volunteers: no

Brief summary:
The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.

Detailed description:

Arms:
arm 1: Aclidinium bromide 400 μg twice-daily by inhalation arm 2: Tiotropium 18 μg once-daily by inhalation arm 3: Placebo

Interventions: intervention 1: Aclidinium bromide 400 μg bid intervention 2: Tiotropium 18 μg once-daily intervention 3: Placebo
Intervention descriptions: intervention 1: Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days. intervention 2: Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days. intervention 3: Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.

Protocol document: